— Know what they know.
Not Investment Advice

TIVC NASDAQ

Tivic Health Systems, Inc.
1W: +4.4% 1M: -40.2% 3M: -68.4% YTD: -78.2% 1Y: -91.4% 3Y: -99.6%
$0.26
Last traded 2026-07-31 — delisted
NASDAQ · Healthcare · Medical - Specialties · $279155 mcap · 1M float · 25.53% daily turnover · Short 44% of daily vol
Smart Money Score
Moderate 50
Insider+$0.0M
Congress—
ETF Holdings—
Key Statistics
Market Cap$0.3M
52W Range0.255-5.6
Volume130,889
Avg Volume262,634
Beta1.83
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOMichael Kevin Handley
Employees52
SectorHealthcare
IndustryMedical - Specialties
IPO Date2021-11-11
1305 E. Houston Street
San Antonio, TX 78205
US
888 276 6888
About Tivic Health Systems, Inc.

Tivic Health Systems, Inc. operates as a late-stage immunotherapeutics company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company’s pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications. In addition, it offers CDMO services. The company was incorporated in 2016 and is based in San Antonio, Texas.

Recent Insider Trades

NameTypeSharesPriceDate
Bolton Sheryle P-Purchase 10,000 $1.04 2026-04-15
Valauri Christina Ri P-Purchase 19,000 $0.95 2026-04-01
Wolf Lisa G M-Exempt 92 — 2026-03-18
Wolf Lisa G M-Exempt 92 — 2026-03-18
Handley Michael K M-Exempt 8,824 — 2026-02-18

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms